The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

What trends did delegates notice, in terms of new modalities, technologies, and approaches? Precision, personalisation, and ...

Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to ...

Op den Kelder grew up in the Netherlands and received his Bachelor’s degree in International Management from Fontys ...

Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

Philippe Masset has been appointed to the Board of Directors at Vect-Horus, a French biotech developing vectors for targeting ...

Stealth refrained from criticising the FDA's decision on its application, which comes after the agency missed its own ...

Angelini is paying $50 million upfront for ex-North American rights to radiprodil, with another $520 million in the offing in ...

The award from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and ...

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...